Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Steroids

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    911 result(s) found for: Steroids. Displaying page 20 of 46.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next» Last»»
    EudraCT Number: 2017-001543-13 Sponsor Protocol Number: HIP-SAP Start Date*: 2018-03-28
    Sponsor Name:Morten Tange Kristensen/Hvidovre Hospital
    Full Title: Preliminary effect and safety of physiotherapy with strength training and protein-dense nutritional supplement in combination with anabolic steroids in cross-continuum rehabilitation of patients wi...
    Medical condition: Area of investigation is recovery of muscle strength and function following hip fracture surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10017287 Fractured hip LLT
    20.1 100000004863 10017299 Fractured neck of femur LLT
    20.1 100000004863 10034736 Pertrochanteric fracture of femur, closed LLT
    20.1 100000004863 10053653 Femur fracture subtrochanteric LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000193-21 Sponsor Protocol Number: 2007-FLUSAL-EL-01 Start Date*: 2008-09-08
    Sponsor Name:Elpen Pharmaceutical Co. Inc.
    Full Title: A multicenter, randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administer...
    Medical condition: Chronic Persistent Asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003561 Asthma, unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001326-25 Sponsor Protocol Number: ACA-SPAI-11-24 Start Date*: 2013-07-25
    Sponsor Name:Fundación SENEFRO
    Full Title: Efficacy and safety of paricalcitol in the reduction of secondary hyperparathyroidism after renal transplantation.
    Medical condition: Secondary hyperparathyroidism after renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    16.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000451-13 Sponsor Protocol Number: 1201 Start Date*: 2012-10-16
    Sponsor Name:Transplant Institute, Sahlgrenska University Hospital
    Full Title: A controlled randomized, open-label, multi-centre study evaluating if a steroid-free immunosuppressive protocol, based on single dose ATG-induction, low tacrolimus-dose and therapeutic drug monitor...
    Medical condition: Prophylaxis of rejection in kidney allograft recipients (by immunosuppression)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10050436 Prophylaxis against renal transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-007794-20 Sponsor Protocol Number: Acute GVHD - ECP Start Date*: 2009-06-10
    Sponsor Name:AKH Wien, Klinik für Innere Medizin I, Onkologie
    Full Title: A randomized controlled open-label multicenter phase II study for initial treatment of acute graft-versus-host disease with extracorporeal photopheresis and corticosteroids or corticosteroids alone
    Medical condition: Patients with newly diagnosed acute GVHD grades II to IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000442-39 Sponsor Protocol Number: Neo-Nivo Start Date*: 2015-08-17
    Sponsor Name:Clinica Universidad de Navarra/Universidad de Navarra
    Full Title: PHASE II STUDY OF NEOADJUVANT NIVOLUMAB IN PATIENTS WITH GLIOBLASTOMA MULTIFORME
    Medical condition: Glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-007329-38 Sponsor Protocol Number: CRODEX01 Start Date*: 2009-02-06
    Sponsor Name:ERYDEL S.P.A.
    Full Title: Multicenter, randomized, double-blind, parallel-group study of intra-erythrocyte dexamethasone versus placebo in patients with steroid-dependent Crohn’s disease
    Medical condition: Patients with steroid-dependent Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006766-21 Sponsor Protocol Number: MINI-SPIOMET Start Date*: 2022-09-02
    Sponsor Name:Hospital de Girona Dr. Josep Trueta
    Full Title: Towards a treatment for accelerated maturation in girls testing spiomet in a randomised placebo controlled, multicentre study.
    Medical condition: Girls with advanced puberty and accelerated bone maturation. Polycystic Ovary Syndrome (PCOS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10014054 Early puberty LLT
    Population Age: Children, Under 18 Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001748-24 Sponsor Protocol Number: ImmCoVA Start Date*: 2020-05-15
    Sponsor Name:Karolinska University Hospital
    Full Title: A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treat...
    Medical condition: COVID-19 infection in patients with respiratory distress.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-005154-11 Sponsor Protocol Number: GECP17/05 Start Date*: 2018-05-31
    Sponsor Name:Spanish Lung Cancer Group (SLCG/GECP)
    Full Title: Phase II non-randomized study of Atezolizumab (MPDL3280A) in combination with Carboplatin Plus Pemetrexed in patients who are chemotherapy-naïve and have stage IV non-squamous non-small cell lung c...
    Medical condition: Atezolizumab combined with carboplatin and pemetrexed
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002607-34 Sponsor Protocol Number: GOIRC-02-2018CHANCETrial Start Date*: 2019-02-20
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: Phase II, open-label study of atezolizumab in a CoHort of pretreated, Advanced Non-small cell lung cancer (NSCLC) patients with rare histologiCal subtypEs – CHANCE trial
    Medical condition: Advanced Non-small cell lung cancer (NSCLC) with rare histological subtypes
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10064049 Lung adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003055-11 Sponsor Protocol Number: TPX-0005-07 Start Date*: 2023-03-27
    Sponsor Name:Turning Point Therapeutics, Inc. (a wholly owned subsidiary of Bristol Myers Squibb Company)
    Full Title: A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harbor...
    Medical condition: Advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001862-12 Sponsor Protocol Number: s63213 Start Date*: 2021-03-23
    Sponsor Name:University Hospitals Leuven, Clinical Trial Centre
    Full Title: Early administration of Vitamin C in patients with sepsis or septic shock in emergency departments: a multicentre, double blinded, randomized controlled trial: the C-EASIE trial.
    Medical condition: We will investigate the potential benefit of early administration of high doses of Vitamin C in addition to standard care in patients with sepsis or septic shock.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001698-22 Sponsor Protocol Number: VRP110330 Start Date*: 2011-04-29
    Sponsor Name:Verona Pharma plc
    Full Title: EVALUATION OF THE EFFICACY AND SAFETY OF 6 REPEATED DAILY DOSES OF NEBULISED RPL554 0.018 mg/kg (6X) IN ALLERGIC ASTHMATICS
    Medical condition: Allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021349-36 Sponsor Protocol Number: VRP100419 (CHDR1018) Start Date*: 2010-11-08
    Sponsor Name:Verona Pharma plc
    Full Title: Randomised, Double-Blind, Placebo-Controlled Evaluation of the Safety and Duration of Action of 2 Single Inhaled Doses, 0.036 mg/kg (12X) and 0.072 mg/kg (24X), of RPL554, a Dual PDE 3/4 Inhibitor,...
    Medical condition: Allergic Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000424-10 Sponsor Protocol Number: UC-0130/1703 Start Date*: 2017-06-16
    Sponsor Name:UNICANCER
    Full Title: A Safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN).
    Medical condition: Patients with recurrent and/or metastatic platinum refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN), with poor prognosis and no effective chemotherapy options.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-003938-18 Sponsor Protocol Number: BY217/M2-125 Start Date*: 2006-01-11
    Sponsor Name:Nycomed GmbH
    Full Title: Effect of roflumilast on exacerbation rate in patients with COPD. A 52 weeks, double-blind study with 500 mcg roflumilast once daily versus placebo
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000623-13 Sponsor Protocol Number: VIR-7831-5008 Start Date*: 2021-07-29
    Sponsor Name:Vir Biotechnology, Inc.
    Full Title: A Phase 3 randomized, multi-center, open label study to assess the efficacy, safety, and tolerability of monoclonal antibody VIR-7831 (sotrovimab) given intramuscularly versus intravenously for the...
    Medical condition: Mild/moderate COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    23.1 10021881 - Infections and infestations 10084401 COVID-19 respiratory infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) AT (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-000443-24 Sponsor Protocol Number: TR02-110 Start Date*: 2011-06-29
    Sponsor Name:Insmed Incorporated
    Full Title: Long Term Safety and Tolerability Study of Open-Label Liposomal Amikacin for Inhalation (Arikace™) in Cystic Fibrosis Patients with Chronic Infection due to Pseudomonas aeruginosa
    Medical condition: Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) BE (Completed) IE (Completed) DE (Completed) FR (Completed) SE (Completed) GR (Completed) AT (Completed) NL (Completed) DK (Completed) BG (Completed) PL (Completed) ES (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001138-32 Sponsor Protocol Number: 208887 Start Date*: 2020-09-18
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study GSK2857916 as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refra...
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Trial now transitioned) NL (Completed) ES (Temporarily Halted) NO (Trial now transitioned) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 09:57:31 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA